Compare VERA & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | CMPS |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2021 | 2020 |
| Metric | VERA | CMPS |
|---|---|---|
| Price | $29.79 | $11.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | ★ $74.20 | $23.75 |
| AVG Volume (30 Days) | 1.6M | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $841.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.05 | $4.88 |
| 52 Week High | $56.05 | $15.87 |
| Indicator | VERA | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 47.04 |
| Support Level | $26.38 | $11.56 |
| Resistance Level | $36.95 | $12.08 |
| Average True Range (ATR) | 1.58 | 0.58 |
| MACD | 0.19 | 0.07 |
| Stochastic Oscillator | 58.65 | 72.86 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.